Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Greta Russler, Bassel Nazha, Sarah Caulfield, Mehmet Asim Bilen, Yuan Liu, Bradley C. Carthon, Sean Evans, Wayne Harris, Omer Kucuk, Jacqueline T. Brown, Viraj A. Master, Jamie M. Goldman, Dylan J. Martini, Lauren Yantorni, Ogul E. Uner, T. Anders Olsen, Julie M. Shabto
Publikováno v:
Clin Genitourin Cancer
Background : Full dose cabozantinib for metastatic renal cell carcinoma (mRCC) is 60mg, but adverse events (AEs) may require dose reductions. Limited data exist comparing efficacy among cabozantinib doses. We compared AEs and clinical outcomes in mRC
Autor:
Paul B. Robbins, Elaine T. Lam, Mehmet Asim Bilen, James Larkin, Alessandra di Pietro, Aly-Khan A. Lalani, Lance C. Pagliaro, Toni K. Choueiri, John B. A. G. Haanen, Eric Voog, Bradley Alexander McGregor, Nikolay Kislov, Bo Huang, Laurence Albiges, Stan Krulewicz, Brian I. Rini, Martin H. Voss
Publikováno v:
Clinical Cancer Research. 28:738-747
Purpose: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. Experimental Design: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component,
Autor:
Syed A. Hussain, Catherine Curran, Giuseppe Di Lorenzo, Ruby Gupta, Pasquale Verolino, Moshe Chaim Ornstein, Petros Grivas, Archana Agarwal, Mehmet Asim Bilen, Jorge A. Garcia, Guru Sonpavde, Alexandra Drakaki, Pedro C. Barata, Gregory R. Pond, Jae-Lyun Lee, Ravindran Kanesvaran
Publikováno v:
Clinical Genitourinary Cancer. 19:425-433
PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the ou
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9
Autor:
Kenneth Ogan, Greta Russler, Jamie M. Goldman, Bassel Nazha, Benjamin Magod, Bradley C. Carthon, Deepak Ravindranathan, Shreyas S. Joshi, Haydn T. Kissick, Yuan Liu, T. Anders Olsen, Wayne Harris, Julie M. Shabto, Omer Kucuk, Jacqueline T. Brown, Subir Goyal, Sarah Caulfield, Lauren Yantorni, Mehmet Asim Bilen, Viraj A. Master, Sean Evans, Dylan J. Martini
Publikováno v:
Oncologist
Background Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There are limited biomarkers for ICI-treated patients with UC. We investigated the association between body composition and c
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Autor:
Limeng Wan, Bradley C. Carthon, Lauren Yantorni, Omer Kucuk, Katherine Emilie Rhoades Smith, Sarah Caulfield, Jacqueline T. Brown, Greta Russler, Bassel Nazha, Mehmet Asim Bilen, Melvin R. Moore, Yuan Liu, Jennifer Ann LaFollette
Publikováno v:
Oncologist
Background Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial
Autor:
Dattatraya Patil, Vikram M. Narayan, Reza Nabavizadeh, Milton Williams, Dylan J. Martini, Kenneth Ogan, Shreyas S. Joshi, Sean Steele, Michelle I. Higgins, Viraj A. Master, Aarti Sekhar, Mehmet Asim Bilen, Sarah P. Psutka
Publikováno v:
Cancer. 127:1974-1983
Background Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual and combined utility of the preoperative skeletal muscle index (SMI) and the modified Glasgow Prognostic Score (
Autor:
Yuan Liu, Julie M. Shabto, Bradley C. Carthon, Lauren Yantorni, Viraj A. Master, Dylan J. Martini, Omer Kucuk, Kenneth Ogan, Mehmet Asim Bilen, Shreyas S. Joshi, Jacqueline T. Brown, Deepak Ravindranathan, Wayne Harris, Sarah Caulfield, Haydn T. Kissick, Emilie Elise Hitron, Greta Russler
Publikováno v:
Oncologist
Background The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved fo
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo